DaVita Inc. Announces Offering of $750 Million Senior Notes

Core Viewpoint - DaVita Inc. has initiated a private offering of $750 million in senior notes due 2033 to manage its financial obligations and support corporate activities [1][2]. Group 1: Offering Details - The offering consists of $750 million aggregate principal amount of senior notes due in 2033 [1]. - The net proceeds from the offering will be used to repay outstanding revolving credit facility borrowings, cover related costs, and for general corporate purposes, including stock repurchases and capital expenditures [2]. Group 2: Regulatory Compliance - The 2033 notes are being offered only to qualified institutional buyers under Rule 144A and to certain non-U.S. persons in compliance with Regulation S [3]. - The offer and sale of the 2033 notes have not been registered under the Securities Act and cannot be sold in the U.S. without registration or an exemption [3][4]. Group 3: Company Overview - DaVita is a healthcare provider focused on transforming care delivery to enhance the quality of life for patients globally, particularly in kidney care [5]. - The company has been a leader in clinical quality and innovation for 25 years, providing care at every stage of kidney health [5].